Ana Andreazza
The next medical frontier: Mitochondria are set to revolutionize disease treatment
The “MitoRevolution” research initiative was recently awarded $23.8 million over six years. The funding will support development of a therapeutic approach that delivers healthy mitochondria directly into damaged cells, promoting regeneration and recovery. “The goal for the end of the project, in six years, is to have a product available through Canadian Blood Services that can be used for any patient that needs it,” says Ana Andreazza, professor in pharmacology and psychology, Scientific Director of MITO2i, and nominated principal investigator on the project.
Mitochondrial transplantation: powering the revolution in regenerative medicine
MITO2i awarded $23.8M NFRF-T grant to pioneer mitochondrial transplantation therapy — an emerging field that could redefine how the world treats organ failure, chronic inflammation, and degenerative diseases.